DDInter1033 DDInter1652
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Leflunomide {u} (Compound) resembles {v} (Compound) Niflumic Acid
Leflunomide {u} (Compound) treats {v} (Disease) systemic scleroderma
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
Leflunomide {u} (Compound) downregulates {v} (Gene) MRPS16
Leflunomide {u} (Compound) causes {v} (Side Effect) Skin nodule
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Losartan
Leflunomide (Compound) resembles Niflumic Acid (Compound)
Leflunomide (Compound) treats systemic scleroderma (Disease)
Leflunomide (Compound) binds PTK2B (Gene)
Leflunomide (Compound) upregulates WIF1 (Gene)
Leflunomide (Compound) downregulates MRPS16 (Gene)
Leflunomide (Compound) causes Skin nodule (Side Effect)
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Losartan